Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042
12 September 2023 - 2:05PM
Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage
biopharmaceutical company developing novel immunotherapies for the
treatment of cancer, announced today the issuance of the first and
foundational patent covering BDC-3042. The U.S. Patent and
Trademark Office (USPTO) issued U.S. Patent 11,753,474 titled
“Anti-Dectin-2 Antibodies,” on September 12, 2023.
“The issuance of this patent is an important milestone in
protecting the composition of matter and methods of treatment for
our BDC-3042 clinical candidate,” explained Justin A. Kenkel,
Ph.D., BDC-3042 co-inventor and Principal Scientist at Bolt
Biotherapeutics. “This patent covers antibodies with a novel
mechanism of action that leverages Dectin-2 agonism to repolarize
tumor-associated macrophages into immunostimulatory, anti-tumor
macrophages. We are on track to enter the clinic with BDC-3042 this
year and are excited by the potential for this new approach to
treat many different types of cancer.”
The claims of the patent will be valid through
May 2041, excluding any patent term adjustments or extensions which
may provide additional protection.
About BDC-3042Bolt Biotherapeutics’
myeloid-modulating antibody, BDC-3042, leverages the power of
myeloid cells to stimulate anti-tumor activity. BDC-3042 is an
agonist antibody targeting Dectin-2, an immune-activating pattern
recognition receptor expressed by tumor-associated macrophages
(TAMs) which are frequently found in the tumor microenvironment.
TAMs play a key role in establishing an immunosuppressive tumor
microenvironment conducive to tumor survival and progression.
BDC-3042 activates Dectin-2, leading to production of an array of
pro-inflammatory cytokines and chemokines and repolarization of
TAMs into immunostimulatory “M1” macrophages. In addition, BDC-3042
treatment induces expression of key antigen presentation machinery,
which helps to expand tumor-reactive T cells and elicit anti-tumor
immunity.
About Bolt Biotherapeutics, Inc. Bolt
Biotherapeutics is a clinical-stage biopharmaceutical company
developing novel immunotherapies for the treatment of cancer. Bolt
Biotherapeutics’ pipeline candidates are built on the Company’s
deep expertise in myeloid biology and cancer drug development. The
Company’s pipeline includes BDC-1001, a HER2-targeting Boltbody™
Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a
myeloid-modulating antibody, and multiple Boltbody ISAC
collaboration programs. BDC-1001 is currently in Phase 2 clinical
development following the successful completion of a Phase 1
dose-escalation trial that demonstrated tolerability and early
clinical efficacy. BDC-3042, an agonist antibody targeting
Dectin-2, is expected to initiate a Phase 1 trial in the second
half of 2023. In preclinical development, BDC-3042 demonstrated the
ability to convert tumor-supportive macrophages to
tumor-destructive macrophages. Bolt Biotherapeutics is also
developing multiple Boltbody™ ISACs in strategic collaborations
with leading biopharmaceutical companies. For more information,
please visit https://www.boltbio.com/
Forward-Looking Statements This
press release contains forward-looking statements about us and our
industry that involve substantial risks and uncertainties and are
based on our beliefs and assumptions and on information currently
available to us. All statements other than statements of historical
facts contained in this press release, including statements
regarding the advancement and success of our clinical trials and
any potential future patent term extensions or adjustments, are
forward-looking statements. In some cases, you can identify
forward-looking statements because they contain words such as
“anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,”
“may,” “on track,” “plan,” “potential,” “predict,” “project,”
“should,” “will,” or “would,” or the negative of these words or
other similar terms or expressions. Forward-looking statements
involve known and unknown risks, uncertainties and other factors
that may cause our actual results, performance, or achievements to
be materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. Forward-looking statements represent our current
beliefs, estimates and assumptions only as of the date of this
press release and information contained in this press release
should not be relied upon as representing our estimates as of any
subsequent date. These statements, and related risks,
uncertainties, factors and assumptions, include, but are not
limited to: the potential product candidates that we develop may
not progress through clinical development or receive required
regulatory approvals within expected timelines or at all; clinical
trials may not confirm any safety, potency or other product
characteristics described or assumed in this press release; such
product candidates may not be beneficial to patients or become
commercialized; patents may not protect our clinical candidates;
and patents may not be extended beyond the normal term. These risks
are not exhaustive. Except as required by law, we assume no
obligation to update these forward-looking statements, or to update
the reasons actual results could differ materially from those
anticipated in the forward-looking statements, even if new
information becomes available in the future. Further information on
factors that could cause actual results to differ materially from
the results anticipated by our forward-looking statements is
included in the reports we have filed or will file with the
Securities and Exchange Commission, including our Annual Report on
Form 10-K for the year ended December 31, 2022. These filings, when
available, are available on the investor relations section of our
website at investors.boltbio.com and on the SEC’s website at
www.sec.gov.
Investor Relations and Media
Contact:
Maeve ConneightonArgot Partners(212)
600-1902boltbio@argotpartners.com
Bolt Biotherapeutics (NASDAQ:BOLT)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Bolt Biotherapeutics (NASDAQ:BOLT)
Historical Stock Chart
Von Mai 2023 bis Mai 2024